CLAIM AMENDMENTS

1. (currently amended) A composition for maintaining a non-enveloped viral vector comprising:

(a) about 1-25% (wt./vol.) trehalose,

(b) about ~~0.05-2~~ 0.05-1.5 mM of a divalent metal salt, ~~a cationic polymer, or a combination thereof,~~

(c) a multiplicity of non-enveloped viral vector particles, and

(d) a liquid carrier.

2. (currently amended) The composition of claim 1, wherein the composition comprises about ~~0.05-2~~ 0.05-1 mM of a divalent metal salt.

3. (currently amended) The composition of claim 2, wherein the composition comprises about ~~0.05-2~~ 0.05-1 mM $MgCl_2$.

4. (original) The composition of claim 2, wherein the composition further comprises a nonionic surfactant in a concentration of about 0.001-0.015% (wt./vol.).

5. (previously presented) The composition of claim 4, wherein the nonionic surfactant is polysorbate 80.

6. (original) The composition of claim 2, wherein the concentration of the multiplicity of non-enveloped viral vector particles is about $1x10^5$ to about $1x10^{13}$ FFU/ml.

7. (original) The composition of claim 2, wherein the osmolality of the composition, in liquid form, is about 150-800 mOsM.

8. (original) The composition of claim 2, wherein the ionic strength of the composition, in liquid form, is about 10-200 mM.

9. (original) The composition of claim 2, wherein the composition further comprises a buffer, such that the pH of the composition is about 6 to about 9 when the temperature of the composition is about 25° C.

10. (original) The composition of claim 2, wherein the composition further comprises about 10-65 mM arginine.

11. (original) The composition of claim 1, wherein the non-enveloped viral vector is an adenoviral vector.

12. (original) The composition of claim 10, wherein the adenoviral vector is replication-deficient.

13. (original) The composition of claim 2, wherein the non-enveloped viral vector is an adenoviral vector.

14. (original) The composition of claim 13, wherein the adenoviral vector is replication-deficient.

15.-26. (canceled)

27. (new) The composition of claim 1, wherein the divalent metal salt is $MgCl_2$.

28. (new) The composition of claim 3, wherein the composition further comprises a nonionic surfactant in a concentration of about 0.001-0.015% (wt./vol.).

29. (new) The composition of claim 28, wherein the nonionic surfactant is polysorbate 80.

30. (new) The composition of claim 3, wherein the concentration of the multiplicity of non-enveloped viral vector particles is about $1x10^5$ to about $1x10^{13}$ FFU/ml.

31. (new) The composition of claim 3, wherein the osmolality of the composition, in liquid form, is about 150-800 mOsM.

32. (new) The composition of claim 3, wherein the ionic strength of the composition, in liquid form, is about 10-200 mM.

33. (new) The composition of claim 3, wherein the composition further comprises a buffer, such that the pH of the composition is about 6 to about 9 when the temperature of the composition is about 25° C.

34. (new) The composition of claim 3, wherein the composition further comprises about 10-65 mM arginine.

35. (new) The composition of claim 3, wherein the non-enveloped viral vector is an adenoviral vector.

36. (new) The composition of claim 35, wherein the adenoviral vector is replication-deficient.

37. (new) The composition of claim 3, wherein the composition further comprises about 0.001-0.015% (wt./vol.) polysorbate 80, the concentration of the multiplicity of non-enveloped viral vector particles is about $1x10^5$ to about $1x10^{13}$ FFU/ml, the osmolality of the composition, in liquid form, is about 150-800 mOsM, the ionic strength of the composition, in liquid form, is about 10-200 mM, and the composition further comprises a buffer, such that the pH of the composition is about 6 to about 9 when the temperature of the composition is about 25° C.

38. (new) The composition of claim 37, wherein the non-enveloped viral vector is a replication-deficient adenoviral vector.